Ramucirumab

• A Phase Ib/II Open-Label, Multicentre Platform Study Evaluating Novel Combinations in Participants with Advanced or Metastatic Non-Small Cel… Pending
  2024-519786-22-01 Phase I/II 7 countries AstraZeneca AB
• Paclitaxel plus ramucirumab and tislelizumab as switch maintenance versus continuation of chemotherapy and tislelizumab in patients with adv… Pending
  2025-524048-36-00 Phase III 3 countries Fondazione GONO G.I.
• Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ… Pending
  2025-524095-27-00 Phase II 2 countries Gilead Sciences Inc.
• A trial to learn how safe different combinations of anti-cancer drugs are and how well they work in adults with advanced or metastatic non-s… Recruiting
  2025-524843-11-00 Phase II 3 countries AstraZeneca AB
• Bemarituzumab in patients with FGFR2b-positive advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed… Recruiting
  2024-512484-31-00 Phase II 2 countries Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
• Volrustomig Priming Regimens Exploratory Phase II Platform Study​ Recruiting
  2023-509482-20-00 Phase II 6 countries AstraZeneca AB
• Substudy 06D: Combination Therapies in 2L Advanced Gastroesophageal Adenocarcinoma Recruiting
  2023-509306-29-00 Phase I/II 4 countries Merck Sharp & Dohme LLC
• A trial to learn how well AZD0901 works and how safe it is compared to standard cancer treatments in adults with advanced and metastatic gas… Ended
  2023-508276-11-00 Phase III 5 countries AstraZeneca AB
• A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRA… Ended
  2023-506241-30-00 Phase III 15 countries Mirati Therapeutics Inc.
• Trastuzumab Deruxtecan for Subjects with HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma after Progression on or A… Ended
  2023-507963-20-00 Phase III 10 countries Daiichi Sankyo Inc.
• PRODIGE 55-SOCRATE : A randomized phase II study to evaluate second-line ramucirumab alone or with paclitaxel in older patients with advance… Ended
  2024-513515-27-00 Phase II 1 country Fondation Franc.Cancerologie Digestive
• A Study of Evorpacept (ALX148) in Patients with Advanced Gastric Cancer Ended
  2023-509406-30-00 Phase II/III 5 countries Alx Oncology Inc.
• A Phase 1/2a study of AFM24 and Atezolizumab in patients with advanced and metastatic cancers Ended
  2024-511999-32-00 Phase I/II 2 countries Affimed GmbH
• A study to investigate the efficacy of ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastat… Ended
  2024-515045-42-00 Phase II 1 country Martin-Luther-Universitaet Halle-Wittenberg
• Ramucirumab plus Irinotecan / Leucovorin / 5-FU versus Ramucirumab plus Paclitaxel in patients with advanced or metastatic adenocarcinoma of… Ended
  2024-512934-14-00 Phase III 3 countries Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
• A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic… Ended
  2024-514269-20-00 Phase III 1 country Eli Lilly & Co.

Showing 1–16 of 16 trials